latest news releases from the newsroom
Maximizer Software Inc.
Maximizer Software Targets Market Rival GoldMine
VANCOUVER, B.C. March 25, 2003 (PRIMEZONE) -- Maximizer Software Inc. (Other OTC:MAXPF) (TSE:MAX), a leading provider of innovative customer relationship management (CRM) and contact management solutions announced today that it plans to go head to head with market rival, Frontrange Solutions Inc. (makers of GoldMine) to win additional customers, business partners and market share.
Petroleum Geo-Services ASA
Petroleum Geo-Services ASA: PGS Trust I Preferred Securities Symbol Change
OLSO, Norway, March 25, 2003 (PRIMEZONE) -- Petroleum Geo-Services ASA ("PGS") (Pink Sheets:PGOGY) (NYSE:PGO) (OSE:PGS) today announced that the Over-The-Counter ("OTC") and Pink Sheet symbol for its PGS Trust I 9 5/8 percent (Other OTC:PGOAY) (Other OTC:PGOAP) Pink Sheet Trust Preferred Securities will change from "PGOAY" to "PGOAP" effective as of Tuesday, March 25, 2003. PGS' American Depositary Receipts (ADRs) currently trade OTC and are quoted on the Pink Sheets under the ticker symbol "PGOGY."
Riddarhyttan Resources AB
Riddarhyttan Resources AB: New Drill Holes Completed in the Suurikuusikko Area
GOTHENBURG, Sweden, March 25, 2003 (PRIMEZONE) -- Riddarhyttan Resources AB (Other OTC:RRHYF): to clarify the information in the press release from March 24, 2003, we release this restructured information. New drill holes completed in the Suurikuusikko area (Finland) demonstrate high gold grades over considerable widths, further highlighting increased gold resource potential both in new zones and depth extensions.
Nissan North America Signs Deal with Intentia
STOCKHOLM, Sweden, March 25, 2003 (PRIMEZONE) -- Leading automotive OEM is seeking higher levels of maintenance efficiency and productivity with less downtime using Movex Plant Maintenance, Intentia's (Other OTC:IAINF) best-of-breed asset management solution.
Biovitrum Initiates Phase II Study with its Diabetes Candidate Drug BVT.3498
STOCKHOLM, Sweden, March 25, 2003 (PRIMEZONE) -- Biovitrum today announced the initiation of a Phase II clinical trial of BVT.3498, its lead compound for type 2 diabetes. The primary end-point of the study is improved glycaemia control. Safety, tolerability and several additional parameters related to the metabolic syndrome will be monitored as well. The placebo-controlled, double blind study will involve more than 100 type 2 diabetes patients at centres in Finland and Sweden.